SEIMEI

SEIMEI is a high-profile startup at the forefront of personalized nutrition and anti-aging solutions, with a strong emphasis on leveraging cutting-edge longevity technology and research partnerships. The company has joined forces with prominent entities such as Human Longevity Inc., a leading research institute in intestinal health, as well as China Baijia Medical, which specializes in longevity technologies, and WuXi AppTec, a well-established CRO. In addition, collaboration with Yipu, a user research firm, has further bolstered SEIMEI's innovative approach. Strategic agreements with industry leaders including Ipsos Group, Silver Economic Think Tank Platform Ageclub, and Zeno Technology have also been established, with the latter culminating in the establishment of the Senmei Zeno Synthetic Biology Joint Laboratory. Established in 2021, SEIMEI operates in the Health Care and Nutrition sectors and recently secured a significant $4.00M investment in a Seed Round led by Emerging Technology Partners, Next Capital 嘉程资本, and Blue Focus PR Consulting on 18 November 2022. This backing further solidifies SEIMEI's position as a standout player in the burgeoning arena of personalized nutrition and anti-aging solutions.